Concerns and Innovations in Tablet Splitting and Scoring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Concerns and Innovations in Tablet Splitting and Scoring
A roundtable discussion of the challenges and innovations in tablet splitting featuring Freeman Technology, Accu-Break Pharmaceuticals, and Medelpharm.

Pharmaceutical Technology
pp. s29-s34

Splitting unscored tablets

PharmTech: What are the problems or risks associated with splitting unscored tablets, especially if they are film-coated or modified release tablets?

Beach (Accu-Break): Splitting unscored tablets is fraught with unpredictability, regardless of the splitting method engaged. Unscored tablets are not designed to be subdivided into reliable and consistent partial doses, and often result in splintered parts with significant loss of mass. Splitting unscored film-coated tablets or modified-release tablets will, in most cases, result not only in an inaccurate medicine dosage, but could also have other undesirable effects. In the case of film-coated tablets, particularly if the film coat is functional (e.g., an enteric coat), the tablet contents could be hydrolysed in the stomach, resulting in profound drug degradation. Similarly with modified-release tablets, fracturing the intact tablet could result in a markedly faster release profile from the broken segments and the production of unwanted side effects because of the overly rapid absorption of the tablet contents. In general, unscored, film-coated tablets should be swallowed whole to avoid untoward effects.

Medelpharm: The main risks are:
  • API dosage control. The risk of uneven pieces and fragments with varying dosages is very high compared with scored tablets. Risks are measured in quality-assurance processes according to the pharmacopoeias.
  • Modification of timed release characteristics. These characteristics can, in some instances, be totally destroyed when a tablet is broken.

To lower the risks and ensure QbD on multilayer tablets designed especially to be split without score marks, you have to create tablets that are real production prototypes and browse the behavior in the whole design space using tableting robots like STYL'ONe.

PharmTech: How different is the tabletting process for scored tablets compared with unscored tablets in terms of the technology and equipments involved, quality control and quality assurance protocols, and stability testing requirements?

Medelpharm: Precision and reliability are even more critical than usual when producing scored tablets. The sensitivity to variance is increased in upscale process, as well as in tablet production. It is important to take note of the following:

  • Before compression, it is crucial to ensure that processes are in place to avoid demixing, segregation, and over-lubrication; classical issues during processing.
  • During compression, there should be tighter regulation control and rejection rules.
  • Uniformity of mass and filling are important parameters. Different weight or uneven filling creates different hardness, which in turn impacts friability and the quality of breaking, as well as uneven filling.

Tooling design is of course crucially important and computer simulation can provide information on stress line inside tablets.

However, only studies of real tablets, opposed to virtual models, on a fully instrumental press like STYLCAM or STYL'One can provide you with data and results rapidly. To further limit your risk, a 'tableting robot' like a STYL'One can browse the design space and help you rapidly select the ideal punch design and production parameters.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here